JPMorgan Chase & Co. Decreases Stock Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

JPMorgan Chase & Co. trimmed its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 21.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 101,059 shares of the medical instruments supplier’s stock after selling 27,324 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.45% of LeMaitre Vascular worth $9,387,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in LMAT. NBC Securities Inc. lifted its position in shares of LeMaitre Vascular by 73.2% in the 3rd quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 183 shares during the last quarter. USA Financial Formulas acquired a new stake in shares of LeMaitre Vascular in the 3rd quarter worth about $60,000. GAMMA Investing LLC increased its holdings in shares of LeMaitre Vascular by 34.3% in the 3rd quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier’s stock worth $68,000 after acquiring an additional 188 shares during the period. Canada Pension Plan Investment Board acquired a new stake in shares of LeMaitre Vascular in the 2nd quarter worth about $82,000. Finally, Acadian Asset Management LLC acquired a new stake in shares of LeMaitre Vascular in the 2nd quarter worth about $104,000. 84.64% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Bridget A. Ross sold 3,750 shares of the business’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $101.47, for a total transaction of $380,512.50. Following the transaction, the director now owns 2,278 shares of the company’s stock, valued at approximately $231,148.66. The trade was a 62.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 10.79% of the stock is currently owned by insiders.

LeMaitre Vascular Stock Performance

LMAT stock opened at $94.17 on Tuesday. The stock has a market cap of $2.12 billion, a P/E ratio of 51.46, a P/E/G ratio of 2.47 and a beta of 0.96. The firm has a 50 day simple moving average of $98.77 and a 200 day simple moving average of $91.48. LeMaitre Vascular, Inc. has a 52 week low of $55.04 and a 52 week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.05. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The firm had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. During the same quarter last year, the firm earned $0.33 earnings per share. The company’s revenue for the quarter was up 15.6% on a year-over-year basis. Sell-side analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, December 5th. Stockholders of record on Thursday, November 21st were given a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.68%. The ex-dividend date of this dividend was Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio is 34.97%.

Analyst Ratings Changes

LMAT has been the topic of several research analyst reports. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Cantor Fitzgerald assumed coverage on shares of LeMaitre Vascular in a research report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price objective for the company. Oppenheimer restated an “outperform” rating and set a $93.00 price objective (up previously from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Finally, Barrington Research raised their price objective on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research report on Friday, November 1st. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $94.57.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.